NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00138593
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT00138528
- Locations
- 🇩🇪
Novartis, Nürnberg, Germany
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 440
- Registration Number
- NCT00138541
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 318
- Registration Number
- NCT00138554
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 418
- Registration Number
- NCT00138515
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00138632
- Locations
- 🇦🇺
Novartis Investigational Site, Sydney, New South Wales, Australia
🇺🇸Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 332
- Registration Number
- NCT00136773
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 325
- Registration Number
- NCT00136799
- Locations
- 🇨🇳
Novartis, Shangai, China
Photodynamic Therapy in Occult-Only Lesions (POOL)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2006-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 202
- Registration Number
- NCT00135837
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00135824
- Locations
- 🇩🇪
Novartis Investigational Site, Heidelberg, Germany
© Copyright 2024. All Rights Reserved by MedPath